Finance

Lists
Outlook: 75.0% bullish·0.0% bearish
Go to analysis
VRTX:NASDAQ
Vertex Pharmaceuticals Inc
$503.82
-0.36%
(-1.82) 1D
Oct 8, 9:46:23 AM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for VRTX...
Open
$503.14
High
$504.11
Low
$499.56
Mkt. cap
127.50B
Avg. vol.
991.35K
Volume
49.17K
P/E ratio
29.27
52-wk high
$560.25
52-wk low
$402.58
EPS
$17.19
Beta
0.28
Shares outstanding
253.46M
No. of employees
6K
Open
$503.14
High
$504.11
Low
$499.56
Mkt. cap
127.50B
Avg. vol.
991.35K
Volume
49.17K
P/E ratio
29.27
52-wk high
$560.25
52-wk low
$402.58
EPS
$17.19
Beta
0.28
Shares outstanding
253.46M
No. of employees
6K
News stories
From web sources and news partners
Profile
Vertex Pharmaceuticals Incorporated is an American biopharmaceutical company based in Boston, Massachusetts. It was one of the first biotech firms to use an explicit strategy of rational drug design rather than combinatorial chemistry. It maintains headquarters in Boston, Massachusetts, and three research facilities, in San Diego, California, and Milton Park, Oxfordshire, England. Wikipedia
About Vertex Pharmaceuticals Inc
CEOReshma Kewalramani
Employees6.4K
Founded1989
HeadquartersBoston, Massachusetts, United States
SectorBiotechnology
Websitevrtx.com
Analyst ratings
Based on 24 analysts giving stock ratings to VRTX in the past 3 months
Strong buy
Buy
21
Hold
3
Sell
0
12-month forecast
Based on 24 Wall Street analysts offering 12 month price targets for VRTX in the last 3 months.
Highest
Current $503.82
$665.00 (+31.99%)
Average
$585.05 (+16.12%)
Lowest
$442.00 (-12.27%)
Analyst
Recommendation
Action
Price target
Projected
Date
Brian Abrahams
RBC Capital
Buy
Maintained
$576.00
+14.3%
10/08/2026
Terence Flynn
Morgan Stanley
Buy
Reiterated
$665.00
+32%
10/07/2026
Tazeen Ahmad
Bank of America Securities
Buy
Maintained
-
-
09/29/2026
Michael Yee
UBS
Buy
Reiterated
$615.00
+22.1%
09/28/2026
Jeffrey Walch
Bernstein
Buy
Maintained
$608.00
+20.7%
09/25/2026
Akash Tewari
Jefferies
Buy
Maintained
$640.00
+27%
09/23/2026
Unknown Analyst
Jefferies
Buy
Maintained
$640.00
+27%
09/23/2026
Salveen Richter
Goldman Sachs
Buy
Maintained
$653.00
+29.6%
09/22/2026
Danielle Brill
Truist Financial
Buy
Maintained
-
-
09/23/2026
Evan Seigerman
BMO Capital
Buy
Reiterated
$600.00
+19.1%
09/23/2026
Louise Chen
Scotiabank
Buy
Maintained
$558.00
+10.8%
09/23/2026
Whitney Ijem
Canaccord Genuity
Hold
Maintained
$442.00
-12.3%
09/23/2026
Paul Matteis
Stifel Nicolaus
Hold
Maintained
-
-
09/22/2026
Geoff Meacham
Citi
Buy
Maintained
$585.00
+16.1%
09/23/2026
Eliana Merle
Barclays
Buy
Maintained
$617.00
+22.5%
09/23/2026
Myles Minter
William Blair
Buy
Maintained
-
-
09/22/2026
Andrew Fein
H.C. Wainwright
Buy
Maintained
$641.00
+27.2%
09/22/2026
Jessica Fye
J.P. Morgan
Buy
Initiated
$560.00
+11.2%
09/11/2026
William Pickering
Bernstein
Buy
Maintained
$608.00
+20.7%
08/11/2026
Naz Rahman
Maxim Group
Buy
Reiterated
$575.00
+14.1%
08/05/2026
Andy Chen
Wolfe Research
Buy
Maintained
$557.00
+10.6%
08/03/2026
Cory Kasimov
Evercore ISI
Buy
Maintained
$535.00
+6.2%
08/04/2026
Mohit Bansal
Wells Fargo
Buy
Reiterated
$550.00
+9.2%
08/04/2026
Joseph Stringer
Needham
Hold
Maintained
-
-
08/04/2026
Carter Gould
Cantor Fitzgerald
Buy
Maintained
$595.00
+18.1%
08/04/2026
Phil Nadeau
TD Cowen
Buy
Reiterated
$550.00
+9.2%
08/04/2026
Sadia Rahman
Wells Fargo
Buy
Reiterated
$550.00
+9.2%
07/13/2026
Brian Skorney
Robert W. Baird
Sell
Maintained
$350.00
-30.5%
07/07/2026
Unknown Analyst
Raymond James
Hold
Maintained
-
-
06/24/2026
Unknown Analyst
Guggenheim
Buy
Maintained
$546.00
+8.4%
06/02/2026
Unknown Analyst
J.P. Morgan
Buy
Maintained
$515.00
+2.2%
05/20/2026
Jay Olson
Oppenheimer
Buy
Maintained
$600.00
+19.1%
05/05/2026
Hans Engel
Erste Group
Hold
Maintained
-
-
05/05/2026
Joon Lee
Truist Financial
Buy
Maintained
$525.00
+4.2%
03/11/2026
Last report
Aug 3, 2026
Fiscal period
Q2 2026
EPS / Est. (USD)
$4.73 / $4.75
-0.32%miss
Revenue / Est. (USD)
3.33B / 3.22B
+3.43%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
3.08B
3.19B
2.99B
3.33B
Cost of goods sold
1.39B
1.44B
1.35B
1.48B
Cost of revenue
1.39B
1.44B
1.35B
1.48B
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
445.10M
487.00M
493.70M
582.20M
Operating expense
445.10M
487.00M
493.70M
582.20M
Total operating expenses
1.84B
1.93B
1.85B
2.07B
Operating income
1.24B
1.26B
1.14B
1.27B
Other non operating income
14.60M
-14.30M
-6.70M
46.20M
EBT including unusual items
1.30B
1.33B
1.25B
1.39B
EBT excluding unusual items
1.35B
1.38B
1.25B
1.42B
Income tax expense
215.90M
139.90M
221.50M
292.00M
Effective tax rate
16.62%
10.51%
17.68%
20.98%
Other operating expenses
-
-
-
-
Net income
1.08B
1.19B
1.03B
1.10B
Net profit margin
35.20%
37.34%
34.53%
32.99%
Earnings per share
4.80
5.03
4.47
4.73
Interest and investment income
125.70M
121.90M
114.80M
120.60M
Interest expense
-3.30M
-3.30M
-
-
Net interest expenses
122.40M
118.60M
114.80M
120.60M
Depreciation and amortization charges
-
-
-
-
EBITDA
1.29B
1.29B
1.19B
1.33B
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps